"The obesity rate in the U.S. is continuing its downward trend. The news comes three years after obesity rates hit a record high. In 2022, almost four out of 10 (39.9%) of Americans met the threshold for the classification, however, the number first began to shrink in 2023. Now, the rate of obesity is now down to 37%, according to new data from Gallup."
""The percentage of adults who report taking this class of medicine specifically for weight loss has increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it," the report explains. The report also notes that far more women are taking the drugs than men (15.2% and 9.7%, respectively), which helps explain why women's obesity rates have dropped off more abruptly."
Obesity prevalence among U.S. adults fell to 37% after peaking at 39.9% in 2022, reversing a trend that began in 2023. Three nationally representative surveys of 16,946 adults indicate a roughly three percentage-point drop, equating to about 7.6 million fewer Americans meeting obesity criteria. Use of GLP-1 medications such as Ozempic, Wegovy, and Zepbound for weight loss rose sharply to 12.4% from 5.8% in February 2024. Women report higher GLP-1 use than men (15.2% versus 9.7%), and the largest obesity reductions occurred among people aged 40–64, groups with higher GLP-1 uptake. Pharmaceutical revenue and new oral drug candidates reflect accelerating demand.
Read at Fast Company
Unable to calculate read time
Collection
[
|
...
]